Adherex Technologies Inc.
TSX : AHX
AMEX : ADH

Adherex Technologies Inc.

November 08, 2005 08:31 ET

Adherex to Present Data at Rodman & Renshaw Conference Indicating Broad Presence of ADH-1 Target on Multiple Cancers

RESEARCH TRIANGLE PARK, NORTH CAROLINA--(CCNMatthews - Nov. 8, 2005) - Adherex Technologies Inc. (TSX:AHX)(AMEX:ADH), a biopharmaceutical company with a broad portfolio of oncology products under development, today announced that the Company will present data relevant to the market potential of ADH-1 (Exherin™) during its presentation November 8, 2005 at 12:40 p.m. ET at the Rodman and Renshaw Techvest 7th Annual Healthcare Conference. The presentation will be webcast live and can be accessed by visiting the Company's website at www.adherex.com. The same data will also be presented today during the Company's presentation at BIOEurope 2005 in Dresden, Germany.

Adherex has undertaken a study of more than 700 tumor samples to define the prevalence of the molecular marker N-cadherin among a variety of tumor types. The Company's research, which is ongoing, shows that among the tumors examined, 100% of liver cancers, 95% of esophageal cancers, 83% of colon cancers, 79% of kidney cancers, and 58% of lung cancers expressed N-cadherin, the target for ADH-1, and thus may be susceptible to ADH-1's anti-tumor activity.

"These data provide some useful parameters for estimating the market potential of ADH-1. Given the expression pattern of N-cadherin, ADH-1 could potentially be active in a number of cancers," said William P. Peters, MD, PhD, MBA, Chairman and CEO. "In fact, in our clinical development to date, we have seen early evidence of anti-tumor activity in patients with esophageal, adrenocortical and colon cancers that expressed N-cadherin."

Peters continued, "While our data suggest broad expression of N-cadherin on multiple tumor types, including some very common ones, the relationship between N-cadherin expression, the quantitative level of that expression and the response to ADH-1 remains under study. There may be other features of a tumor, for example, expression of other markers or sensitivity to other therapy that could affect the response to ADH-1. Importantly, the data provide us additional guidance in selecting patients to include in our clinical studies, enhancing the probability of useful outcomes."

In conjunction with its presentation of data on N-cadherin expression across tumor types, the Company has posted a document with further discussion on the potential market size of ADH-1 on its website at www.adherex.com.

About Adherex Technologies

Adherex Technologies Inc. is a biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics. We aim to be a leader in developing innovative treatments that address important unmet medical needs in cancer. We currently have multiple products in the clinical stage of development, including ADH-1 (Exherin™), eniluracil and sodium thiosulfate (STS). ADH-1, our lead biotechnology compound, selectively targets N-cadherin, a protein present on certain tumor cells and established blood vessels that feed solid tumors. Eniluracil, an oral dihydropyrimidine dehydrogenase (DPD) inhibitor, was previously under development by GlaxoSmithKline for oncology indications. STS, a drug from our specialty pharmaceuticals pipeline, protects against the disabling hearing loss that can often result from treatment with platinum-based chemotherapy drugs. With a diversified portfolio of unique preclinical and clinical-stage cancer compounds and a management team with expertise in identifying, developing and commercializing novel cancer therapeutics, Adherex is emerging as a pioneering oncology company. For more information, please visit our website at www.adherex.com.

This press release contains forward-looking statements that involve significant risks and uncertainties. The actual results, performance or achievements of the Company might differ materially from the results, performance or achievements of the Company expressed or implied by such forward-looking statements. Such forward-looking statements include, without limitation, those regarding the utility or impact of the N-cadherin expression data on our clinical studies or the market potential of our product candidates. We can provide no assurance that such utility or impact will be realized. We are subject to various risks, including those inherent in the biopharmaceutical industry, the early stage of our product candidates, the uncertainties of drug development, clinical trials and regulatory review, our reliance on collaborative partners, our need for additional capital to fund our operations, and our history of losses. For a more detailed discussion of related risk factors, please refer to our public filings available at www.sedar.com and www.sec.gov.

Contact Information

  • Adherex Technologies Inc.
    Melissa Matson
    Director, Corporate Communications
    (919) 484-8484
    matsonm@adherex.com